@article {Heudebert:March 2000:0884-8734:175, author = "Heudebert, Gustavo R.", author = "Centor, Robert M.", author = "Klapow, Joshua C.", author = "Marks, Robert", author = "Johnson, Lawrence", author = "Wilcox, C. Mel", title = "What Is Heartburn Worth?: A Cost-Utility Analysis of Management Strategies", journal = "Journal of General Internal Medicine", volume = "15", year = "March 2000", abstract = "OBJECTIVE:

To determine the best treatment strategy for the management of patients presenting with symptoms consistent with uncomplicated heartburn. METHODS:

We performed a cost-utility analysis of 4 alternatives: empirical proton pump inhibitor, empirical histamine2-receptor antagonist, and diagnostic strategies consisting of either esophagogastroduodenoscopy (EGD) or an upper gastrointestinal series before treatment. The time horizon of the model was 1 year. The base case analysis assumed a cohort of otherwise healthy 45-year-old individuals in a primary care practice. MAIN RESULTS:

Empirical treatment with a proton pump inhibitor was projected to provide the greatest quality-adjusted survival for the cohort. Empirical treatment with a histamine2 receptor antagonist was projected to be the least costly of the alternatives. The marginal cost-effectiveness of using a proton pump inhibitor over a histamine2-receptor antagonist was approximately $10,400 per quality-adjusted life year (QALY) gained in the base case analysis and was less than $50,000 per QALY as long as the utility for heartburn was less than 0.95. Both diagnostic strategies were dominated by proton pump inhibitor alternative. CONCLUSIONS:

Empirical treatment seems to be the optimal initial management strategy for patients with heartburn, but the choice between a proton pump inhibitor or histamine2-receptor antagonist depends on the impact of heartburn on quality of life.", pages = "175-182(8)", url = "http://www.ingentaconnect.com/content/bsc/jgi/2000/00000015/00000003/art00005" doi = "doi:10.1046/j.1525-1497.2000.02639.x" }